Related Experiment Video
Updated: May 31, 2026

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
Published on: May 24, 2016
CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy
Christopher F Spurney1, Carolina Tesi Rocha, Erik Henricson
1Children's National Medical Center, George Washington University, Washington, DC, USA.
Introduction:
Corticosteroid treatment slows disease progression and is the standard of care for Duchenne muscular dystrophy (DMD). Coenzyme Q10 (CoQ10) is a potent antioxidant that may improve function in dystrophin-deficient muscle.
Methods:
We performed an open-label, "add-on" pilot study of CoQ10 in thirteen 5-10-year-old DMD patients on steroids. The primary outcome measure was the total quantitative muscle testing (QMT) score.
Results:
Twelve of 16 children (mean age 8.03 ± 1.64 years) completed the trial. Target serum levels of CoQ10 (≥2.5 microg/ml) were shown to be subject- and administration-dependent. Nine of 12 subjects showed an increase in total QMT score. Overall, CoQ10 treatment resulted in an 8.5% increase in muscle strength (P = 0.03).
Conclusions:
Addition of CoQ10 to prednisone therapy in DMD patients resulted in an increase in muscle strength. These results warrant a larger, controlled trial of CoQ10 in DMD.
More Related Videos
Related Concept Videos
Satellite Stem Cells and Muscular Dystrophy
COPD: Management Using Bronchodilators and Corticosteroids
Clinical Trials
There are four phases in a clinical trial. A phase one...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Rheumatic Heart Disease III: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy

